MRNS
Companies
NASDAQ
Marinus Pharmaceuticals Inc.
Health Care
$0.55
+$0.18 (+48.09%)
Price Chart
Overview
About MRNS
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
Market Cap
$83.5M
Volume
12.1
Avg. Volume
316.3
P/E Ratio
Dividend Yield
0.00%
Employees
154.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.95
High Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, MRNS shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$83.5M
Volume12.1
P/E Ratio
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 3, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025